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tion, during CZP maintenance therapy response was similar 
as compared to anti-TNF experienced patients as well as be-
tween patients with a short (0–5 years) vs. long duration of 
disease (>5 years).  Conclusions: CZP is an effective long-term 
treatment option, including CD patients with long disease 
duration and prior treatment with 1 or 2 anti-TNF agents. 
 © 2017 S. Karger AG, Basel 
 Introduction 
 The introduction of tumor necrosis factor (TNF)-in-
hibiting drugs emerged as the beginning of a new era in 
the treatment of inflammatory bowel disease (IBD) with 
infliximab in 1997 constituting the first approved agent 
for the treatment of Crohn’s disease (CD)  [1] . Shortly 
thereafter, this pharmacodynamic principle of treatment 
likewise was approved for ulcerative colitis (UC). Since 
the beginning of the anti-TNF era, the armamentarium of 
anti-TNF agents available for CD was always bigger com-
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 Abstract 
 Background: Long-term data of certolizumab pegol (CZP) in 
Crohn’s disease (CD) from pivotal registry trials are limited. 
We therefore aimed to evaluate the long-term efficacy of CZP 
in clinical practice in Switzerland.  Methods: In the First Ap-
proved Certolizumab Therapeutic Experience in Switzer-
land-III phase IV multicenter cohort, patients receiving CZP 
were prospectively included all over Switzerland in (non-) 
academic hospitals and private practice.  Results: We includ-
ed 104 CD patients (52 male; only 22.1% anti-tumor necrosis 
factor (TNF) naïve, CZP as third anti-TNF agent in 46.2%) with 
follow-up time between 6 weeks up to 5 years. During treat-
ment with CZP, we observed a significant decrease of the 
Harvey Bradshaw Index from a median of 7 at baseline (inter-
quartile range 4–11) to 4, 5, 4, 3, 3, and 2 at weeks 6, 26, 52, 
78, 104, and 156, respectively. While anti-TNF naïve patients 
showed a significantly better response at the end of induc-
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pared to the one for UC, from the introduction of adali-
mumab in 2004  [2] – approved for UC only about 7 years 
later  [3] – and shortly thereafter certolizumab pegol 
(CZP)  [4] , which never was systematically tested in UC. 
In contrast, clinicians in most countries of the world are 
currently faced with the situation that less anti-TNF 
agents are available nowadays for CD (with 2 agents, 
namely infliximab and adalimumab), as CZP is approved 
only in the USA, Russia, and Switzerland. In UC, how-
ever, after the recent introduction of golimumab  [5] , now 
in most western countries, 3 TNF-inhibitors are approved 
and available for treatment.
 Once the decision to initiate a TNF-inhibiting drug in 
the treatment of CD patients has been made, there are sev-
eral reasons to necessitate switching the agent including 
primary non-response and loss of response (LOR)  [1, 2, 4, 
6] . This strategy has revealed considerable clinical rates of 
success  [2, 6–8] . Moreover, in clinical practice in a non-
negligible fraction of patients, the treating physician is 
forced to select an alternative TNF inhibitor despite treat-
ment success in view of side effects, such as infusion reac-
tions  [9, 10] , or paradoxical TNF inhibitor-induced pso-
riasiform skin lesions  [11] (which in some instances may 
re-occur promptly after a switch to another anti-TNF 
agent, whereas in other cases can be adequately addressed 
by switching  [12] ). Therefore, the availability of a selection 
of agents within the class of TNF inhibitors is certainly a 
need for the practicing clinician in the treatment of CD.
 While the available data on CZP from PRECiSE I  [7] , 
II  [13] , III  [14] found on a robust basis of large random-
ized and controlled trials, current long-term or clinical 
real life data are still sparse. Nevertheless, the results from 
PRECiSE III, a prospective, open-label extension trial, 
where patients completing PRECiSE II could be included, 
revealed clinical efficacy of continuous CZP in respond-
ers to induction therapy for a maximal observation peri-
od of up to 18 months  [14] and suggest a therapeutic 
long-term potential for CZP in CD. 
 Previously, we reported on the efficacy and safety of 
CZP induction treatment in an unselected CD patient 
population in clinical real life, observing rates of response 
and remission of 54 and 40%, respectively (First Approved 
Certolizumab Therapeutic Experience in Switzerland 
[FACTS] survey)  [15] . The consecutive extension of the 
observation period to 6 months identified a sustained clin-
ical efficacy (FACTS II)  [16] in this CD population. We 
herein report on the multicenter long-term observation of 
CD patients treated with CZP in Switzerland by physicians 
participating in the FACTS I and II surveys as well as CD 
patients included thereafter.
 Methods 
 Study Design and Questionnaires 
 All Swiss gastroenterologists were invited to participate in a 
questionnaire-based survey of all patients treated with CZP since 
the first approval of the drug in Switzerland in 2007. We previ-
ously reported on the results of induction therapy (FACTS  [15] ) 
as well as further clinical course up to week 26 (FACTS II  [16] ). 
In accordance to the PRECiSE studies, data were collected at base-
line (week 0) directly prior to induction with CZP, week 6 (follow-
ing induction treatment at weeks 0, 2, and 4) and at week 26 for 
FACTS I and II. Details on questionnaires have been described 
previously  [15, 16] . We now report on the long-term extension of 
this survey. All patients included in FACTS I/II were followed up 
by physician chart review (M.S.). In addition, all gastroenterolo-
gists, who included 1 patient, were addressed and further CD pa-
tients treated with CZP were included in this long-term analysis. 
The data collection period lasted from April 3, 2008, to October 
30, 2014. 
 Evaluation of Disease Activity, Efficacy, and Drug Safety Issues 
 CD activity was measured, in agreement with existing data on 
CZP, by the Harvey Bradshaw Index (HBI), known to correlate 
closely with the CD Activity Index (CDAI)  [17, 18] . In 2006, Best 
 [19] evaluated the 2 scores by regression modelling and found that 
a 1-point increase in HBI corresponds to a 27-point increase in the 
CDAI. According to the European Crohn’s and Colitis Organiza-
tion guidelines for the definition of CD activity  [20], we applied the 
following definitions: an HBI from 0 to 4 points indicates clinical 
remission (corresponding to a mean CDAI from 26 ± 26 to 134 ± 
39), an HBI from 5 to 7 points indicates mild disease (CDAI: 161 ± 
42 to 216 ± 49), an HBI from 8 to 15 indicates moderate disease 
(CDAI: 243 ± 52 to 432 ± 75), an HBI >15 indicates severe disease 
(CDAI  ≥ 459 ± 78). We defined clinical remission as an HBI  ≤ 4. 
 The questionnaires assessed frequency and type of adverse reac-
tions and recorded the following items: injection site reaction, al-
lergic reaction outside injection site, headache, gastrointestinal 
complaints (not CD-related), bleeding, infection, perianal/perineal 
abscess, and other adverse events. The items were classified accord-
ing to their probability of being related to CZP into “unclassifiable,” 
“conditional,” “unlikely,” “possible,” “probable,” and “certain” ac-
cording to the WHO definitions of causality assessment  [21] .
 Inclusion and Exclusion Criteria 
 All CD patients treated with CZP since its approval in Switzerland 
in September 2007 were eligible, provided that their diagnosis of CD 
was established on the basis of standard clinical, endoscopic, and his-
tologic criteria at least 6 months prior to inclusion  [22] . Patients were 
excluded if induction treatment with CZP was not performed accord-
ing to the label (e.g., only 1 CZP injection), which recommends treat-
ment with 400 mg s.c. at weeks 0, 2, and 4.
 Statistical Analysis 
 The statistical analyses were performed using SPSS version 21 
(IBM, Armonk, NY, USA) and Prism version 6 (GraphPad Soft-
ware, La Jolla, CA, USA). Results of quantitative data are present-
ed as median plus interquartile ranges (IQR) for nonparametric 
data or mean ± SD and range for parametric data, whereas cate-
gorical data are summarized as the percentage of the group total. 
For nonparametric comparisons, the Wilcoxon matched-pairs 
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signed rank test and Mann-Whitney test were used to analyze 
paired and non-paired data, respectively. Chi-square testing was 
applied to test for difference among categorical variables.
 Results 
 Patients Characteristics 
 A total of 104 patients (52 men) were included with first 
CZP dose between November 2007 and August 2013 with 
a follow-up between 6 weeks up to 5 years (median 56 
weeks, IQR 26–104) with last evaluation conducted at the 
end of October 2014. The median age of the patients was 
36 years (IQR 29.25–48.75 years) with a median disease 
duration of 10 years (IQR 3.25–15 years). The majority of 
patients receiving CZP were experienced to anti-TNF 
treatment with only 22% previously not having received 
TNF-inhibiting drugs, thus CZP representing their first 
anti-TNF agent. While almost half of patients (45%) had 
previously received infliximab and adalimumab (both are 
available for the indication CD in Switzerland), 29% had 
previously been treated with infliximab and 2% with adali-
mumab only (previous treatment with anti-TFN un-
known in 2%). An overview of the most important base-
line characteristics as well as previous and ongoing medi-
cation use including reasons for cessation is given in 
 Table 1 and  Figure 1 , respectively.
 Evolution of Disease Activity during CZP Treatment 
and Continuation of Treatment 
 At baseline, according to HBI, 11.5% had severe (HBI 
of >15), 26.9% moderate (HBI 8–15), and 26.9% mild dis-
ease (HBI 5–7), while 27.9% were in remission (HBI <5). 
Among the latter group of patients underlying reasons 
for CZP initiation were either one or a combination of 
the following factors: previous intolerance/side effects to 
IFX or ADA (41.4 and 3.4%, respectively), previous sur-
gery (34.5%) and active perianal disease (fistulae and/or 
abscess, 31%). During treatment with CZP, we observed 
a significant decrease of HBI from a median of 7 (IQR 
4–11) at baseline to 4 ( p = 0.017), 5 ( p = 0.063), 4 ( p = 
0.002), 3 ( p = 0.009), 3 ( p < 0.001), and 2 ( p < 0.001) at 
weeks 6, 26, 52, 78, 104, and 156, respectively. Median 
HBI remained low at weeks 208 and 260 with 5 and 3, 
respectively ( Fig. 2 a). However, due to the small number 
of patients at these time points (7 and 4, respectively), no 
significant differences were seen. While the number of 
patients on CZP progressively decreased during the fol-
low-up time of variable duration, the decreases in HBI 
translated into increased rates of remission among those 
0 20 40 60 80 100
ADA
IFX
MTX
AZA/6-MP
Prednisone
Budesonide
Never
Loss of response
Other reasons
No/insufficient response
Side effects intolerance
Still ongoing
Unknown
Percentage
 Fig. 1. Previous medication prior to induction with CZP. Prior use 
of medication is shown including ongoing intake depicted in or-
ange where applicable. Whenever available, reasons for prior dis-
continuation are provided.  
Table 1.  Patient characteristics
Gender, male, % 50
Current age, years, median (IQR) 36 (29.3–48.8)
Age at diagnosis, years, median (IQR) 24.5 (19.3–35.5)
Disease duration, years, median (IQR) 10 (3.3–15)
Age at diagnosis (montreal), years, %
1 (<16) 9.6
2 (17–40) 75
3 (>40) 15.4
Unknown 0
Localization (Montreal), %
1 (ileal) 13.4
2 (colonic) 63.5
3 (ileocolonic) 21.2
Unknown 1.9
Behavior (Montreal), %
1 (non-stricturing, non-penetrating) 25
2 (structuring) 25
3 (penetrating) 46.2
Unknown 3.8
Disease duration, years, %
<1 7.7
1–2 6.7
2–5 12.5
>5 68.3
Unknown 4.8
Previous surgery, %
No 52.9
Ileal 1.9
Ileal-cecal 26.9
Colonic 9.6
Unknown 8.7
Active smoking, yes, % 33.7
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patients with ongoing CZP treatment with 41.4, 40.7, 
51.9, 58.1, 53.6, and 73.3% at weeks 6, 26, 52, 78, 104, and 
156, respectively, compared to 27.9% at baseline ( p < 
0.01;  Fig. 2 b). As mentioned above, the duration of fol-
low-up was variable with a shorter interval in those pa-
tients included later during the course of the study. At the 
end of follow-up, 34.6% of patients continued CZP. Ac-
cording to the points in time of evaluation by the physi-
cians, among those patients reaching the weeks 6, 26, 56, 
78, 104, 156, 208, and 260, respectively, 85.6, 62.5, 46.7, 
39.8, 31.7, 32.4, 31.6, and 30.8% continued CZP treat-
ment ( Fig. 2 b). An overview on the reasons underlying 
cessation of CZP administration for patients overall and 
separated according to early (within <1 year) and late (af-
ter  ≥ 1 year) treatment withdrawal is provided in  Figure 
2 c.
 Evolution of Disease Activity According to Previous 
Anti-TNF Treatment and Disease Duration 
 Comparing HBI in the relatively small subset of anti-
TNF naïve patients ( n = 22) to those previously exposed 
to 1 or 2 TNF inhibiting agent(s), we did not observe 
significant differences in baseline disease activity. How-
ever, TNF naïve patients revealed to have a significantly 
better treatment response directly after induction thera-
py at week 6 ( p = 0.001). During complete follow-up 
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8%
3%
15% 59%
12%
24%
29%
25% 44%
4%
9%
22%
4%
4%
Patients overall
Stop within <1 year
Stop after ?1 year20%c
 Fig. 2.  a–c Evolution of HBI during CZP treatment and reasons for 
cessation of treatment. Box plots of HBI values at the different 
times of follow-up are depicted in ( a ) with mean values as black 
dots within the boxplots (boxes represent IQR, whiskers 5–95 per-
centile, outliers are not shown). Levels of significance are provided 
(ns, not significant; asterisks represent small sample size, that is, 
<10 patients). Corresponding levels of remission during follow-up 
are provided in ( b ), including the number of patients at risk (at 
follow-up at) each observational point. The reasons for cessation 
of CZP administration are depicted in ( c ) for patients overall, as 
well as according to those patients with early and late treatment 
withdrawal, defined ad stopping CZP within <1 and  ≥ 1 year after 
first dose, respectively. 
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treatment, response in TNF naïve patients also tended to 
be better compared to their counterparts previously hav-
ing received anti-TNF treatment. However, this differ-
ence was not significant ( Fig. 3 a). Treatment duration in 
the anti-TNF naïve patients was not higher compared to 
patients previously treated with TNF inhibitors. Indeed, 
in the latter, mean treatment duration was even higher 
with 73.8 vs. 67.5 months ( p < 0.001). Next, we aimed to 
investigate whether response to CZP differed for pa-
tients with previous exposure to 2 anti-TNF agents com-
pared to those having received only one agent. Although 
disease activity was higher at baseline in the former 
group only a slight trend toward higher activity remained 
at the end of the observation period and this difference 
was not significant ( Fig.  3 b). Moreover, we compared 
disease activity during CZP induction and maintenance 
between patients with a shorter (0–5 years) vs. longer (>5 
years) disease duration. While HBI was similar at base-
line and after induction (week 6) between both groups 
of patients, response after 6 months of treatment was 
significantly better in the long vs. short disease duration 
patients corresponding to a median HBI of 7.5 vs. 4 ( p = 
0.014). This was also seen at week 52 and 78 by trend 
with however no significant difference ( Fig. 3 c). 
 Disease Activity at End of Follow-Up 
 At the last follow-up evaluation, which occurred at a 
median of 56 weeks after the initiation of CZP induction 
treatment (IQR 26–104 weeks), the median HBI at end of 
follow-up was significantly lower in anti-TNF naïve pa-
tients (3 vs. 8 in patients previously having received anti-
TNF,  p = 0.043; with a median HBI of 6 in the cohort 
overall). In contrast, no significant differences were ob-
served within the anti-TNF experienced patients between 
those previously having received 1 vs. 2 agents as well as 
between patients with a disease duration of 0–5 vs. >5 
years ( Fig. 4 ).
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 Fig. 3.  a–c Evolution of HBI during CZP treatment according to 
subgroups. Box plots of HBI values at the different times of follow-
up are depicted (with black lines as mean values) for anti-TNF ex-
perienced vs. naïve ( a ) patients, patients previously treated with 1 
vs. 2 anti-TNF agents ( b ), and patients with a disease duration of 
0–5 vs. >5 years ( c ). 
 Fig. 4. HBI at end of follow-up. Box plots of HBI values at the last 
point of follow-up for the cohort overall and according to the sub-
groups mentioned in the legend for  Figure 3 . 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
10
9 
- 1
/1
1/
20
18
 8
:3
3:
00
 A
M
 Vavricka   et al.  Dig Dis 2017;35:423–432 
DOI: 10.1159/000475494
428
 At end of follow-up, CZP was continued in 36 patients 
(i.e., 34.6% of all patients included) with no significant dif-
ferences between anti-TNF naïve (30.4%) and experienced 
(overall: 35.8%; one previous agent: 34.4%, 2 previous 
agents: 36.7%) and those patients with a shorter (0–5 years, 
24.2%) vs. longer disease duration (>5 years, 39.4%, ns).
 Safety and Adverse Events 
 No events of tuberculosis, cancer, lymphoma, or death 
were reported. An overview on the nature, time points, 
and frequencies (both absolute numbers and in percent-
age of patients at risk at each given time point) of report-
ed adverse events is provided in  Table 2 . Allergic reac-
tions reported included pruritus, increase of arthralgia, 
exanthema including 1 case of a possible pityriasis rosea, 
and injection site reactions with local redness, itching, 
and pain. None of these led to cessation of the drug. How-
ever, there was one 30-year-old male patient developing 
severe limb pain, fever, dyspnoea, nausea, myalgia, and a 
full body exanthema classified as probably related to CZP 
and entailing stop of the agent at week 6. Furthermore, a 
36-year-old female patient developed progressive myal-
gia in the extremities (again rated as probable related to 
CZP), also resulting in CZP withdrawal at week 104. In-
fections observed were cases of urocystitis, sinusitis, and 
bronchitis. In addition, single cases of bacterial vaginosis, 
Table 2.  Adverse events according to weak of treatment are depicted
Injection site 
reaction
Allergic reaction 
outside of 
injection site
Headache/
migraines
Gastrointestinal 
(not Crohn’s 
worsening)
Bleeding Infection Perineal/
perianal 
abscess
Other
W6
Definite 1 (1) 3 (2,9) 1 (1) – – – – 4 (3.8)
Probable – 2 (1.9) – – 1 (1) – – 2 (1.9)
Possible 1 (1) 2 (1.9) 1 (1) 6 (5.8) 1 (1) 3 (2.9) – 3 (2.9)
Sum 2 (1.9) 7 (6.7) 2 (1.9) 6 (5.8) 2 (1.9) 3 (2.9) – 9 (8.7)
W26
Definite 1 (0) 1 (1.1) 1 (1.1) – – 1 (1.1) – 1 (1.1)
Probable – 1 (1.1) 2 (2.2) – – 1 (1.1) – 3 (3.3)
Possible – 2 (2.2) 1 (1.1) 4 (4.4) 1 (1.1) 2 (2.2) – 5 (5.5)
Sum 1 (0) 4 (4.4) 4 (4.4) 4 (4.4) 1 (1.1) 4 (4.4) – 9 (9.9)
W56
Definite – – 1 (1.9) – – – – 1 (1.9)
Probable – – – 1 (1.9) – – – 1 (1.9)
Possible – – 1 (1.9) 2 (3.8) – – 2 (3.8) 3 (5.8)
Sum – – 2 (3.8) 3 (5.8) – – 2 (3.8) 5 (9.6)
W78
Definite – – – – – – – 1 (3.2)
Probable – – – – – – – –
Possible – – – – – – – 1 (3.2)
Sum – – – – – – – 2 (6.5)
W104
Definite – 1 (3.6) – 1 (3.6) – – – 1 (3.6)
Probable 1 (0) – – – – – – –
Possible – – 2 (7.1) – – 1 (3.6) – –
Sum 1 (0) 1 (3.6) 2 (7.1) 1 (3.6) – 1 (3.6) – 1 (3.6)
W156
Definite – – – – – – – –
Probable – – – – – – – –
Possible – 1 (6.7) – 1 (6.7) – – – 1 (6.7)
Sum – 1 (6.7) – 1 (6.7) – – – 1 (6.7)
 Each occurrence of an adverse event was rated by the treating physician as definite, probable, possible or not related to the adminis-
tration of CZP. Those events not considered to be related to the drug are not shown here. Crude number for any adverse event given are 
depicted according to the likelihood of relation to drug exposure including the sum of the 3 categories.
In brackets, percentage for any adverse event according to the patient number at risk at any given observational point are shown.
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enoral infection of a tooth, herpes labialis, skin abscess as 
well as an infection of a port-a-cath were reported. Gas-
trointestinal symptoms including constipation, meteor-
ism, nausea, and vomiting were felt to be at least possibly 
related to CZP administration. Two patients reported 
some irregularities with menstrual cycle and menome-
trorrhagia. Other adverse events with possible, probable, 
or definitive causal association to CZP were paresthesia, 
fatigue, hair loss, dry eyes, psoriasiform skin reaction, 
muscle cramps, dysgeusia, night sweat, depressive symp-
toms, and edema.
 Discussion 
 In this open-label multicenter observational study, we 
report on the results of long-term treatment with CZP in 
CD in a clinical real-life setting with participating gastro-
enterologists from private practice and academic as well 
as non-academic medical centers in Switzerland. Our re-
sults demonstrate that CZP is an effective long-term 
treatment option to achieve and maintain clinical re-
sponse and remission in an unselected and vastly treat-
ment-experienced CD patient population. 
 Until now, there was a lack of clinical long-term data 
with CZP beyond a treatment period of 6 (PRECiSE II 
 [13] and FACTS II  [16] ) and 18 (PRECiSE III  [14] ) 
months, respectively. In view of this and the well-estab-
lished considerable LOR rates with anti-TNF-agents, par-
ticularly within the first year of treatment, yet also con-
tinuously thereafter  [6] long-term data are important for 
the practicing clinician involved in the care of CD pa-
tients. In congruence with the clinical experience with 
other agents, in our cohort, the fraction of patients with 
cessation of CZP is highest within the first year of treat-
ment. However, our data with an observational period of 
up to 5 years indicate that those patients staying on the 
drug beyond 12–18 months experience a sustained clini-
cal benefit. The rates of treatment cessation may appear 
high in our cohort. However, besides the fact that our pa-
tient cohort was highly treatment experienced with al-
most every second patient having received CZP as the 
third anti-TNF agent, a similar fraction of patients re-
mained on CZP after 26 weeks compared to PRECiSE II, 
that is, 62.5% in our cohort vs. 69.9% in PRECiSE II (here, 
however, only those roughly two-thirds of patients re-
sponding to induction treatment were considered for 
maintenance therapy)  [13] . Both, this selection of re-
sponders after induction and also the intermittent pla-
cebo phase between weeks 6 and 26 in the design of 
 PRECiSE II in conjunction with the baseline characteris-
tics with less than 20% of patients with prior infliximab 
exposure (and none with previous treatment with adali-
mumab) in rigorous contrast to our extensively anti-
TNF-experienced cohort precludes a decent comparison 
of our data to the results from PRECiSE III  [14] . Never-
theless, our results clearly imply that CZP is a valuable 
and effective long-term treatment option for a substantial 
fraction of – even difficult-to-treat – CD patients. More-
over, the long-term safety profile of CZP appears to be 
favorable with a frequency of mild-moderate (and no se-
vere) adverse events as expected from the previous litera-
ture in the first months of treatment and only few inci-
dents thereafter  [23–26] .
 As expected, naïve patients (the vast minority in our 
study, only 1 in 5 patients) had a significantly better re-
sponse after induction at week 6. However, in the further 
course of treatment, no significant differences in clinical 
benefit were observed according to prior anti-TNF expo-
sure. In general, in virtually all biological agents tested in 
IBD and even in the emerging small molecules, efficacy 
rates were found to be higher in anti-TNF naïve patients 
as compared to those with previous exposure. Underlying 
reasons for this difference remain somewhat elusive. The 
traditional and often reported explanation considers pre-
vious anti-TNF exposure being a surrogate marker of a 
more severe course of disease and also one that is more 
difficult to therapeutically address. However, as the inter-
pretation of the investigators conducting the phase II tri-
al of ustekinumab  [27] illustrates, explanations may be 
primarily driven by the results obtained at that time point 
and not necessarily by a critical review of the available 
overall evidence. Initially, a presumable superiority of 
this agents in patients previously exposed to infliximab – 
at that time explained by an alternate immunological 
pathway (i.e., for instance rather TH17 than TNF-α) in 
this subgroup of patients – was refuted in the subsequent 
phase III study  [28] , revealing significantly superior effi-
cacy rates in anti-TNF naïve CD patients, leading to a re-
naissance of the traditional explanation (previous anti-
TNF exposure = indicative of a generally more severe 
course of disease). Interestingly, the phase II ustekinum-
ab had an identical number of participating patients as 
our long-term observational study (104 patients). This 
example illustrates that conclusions on diverging efficacy 
between subgroups of patients in such a relatively small 
patient number have to be drawn with great caution and 
may be misleading if subsequently tested in a larger pa-
tient group. Therefore, we cannot definitely state whether 
there indeed may be a difference as compared to inflix-
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imab or adalimumab, in that efficacy rates in naïve vs. 
previously exposed align on the long-term to a compa-
rable overall efficacy, or whether this observation rather 
is erroneous, as for instance due to a small case number 
or a potential source of bias.
 As total CZP treatment duration was not shorter in the 
experienced group of patients (indeed a longer overall 
mean treatment duration was seen in our cohort), this 
beneficial effect cannot be explained by a bias due to pref-
erential premature treatment withdrawal in anti-TNF-
experienced patients. Accordingly and despite the words 
of caution expressed in the previous sentences, one of the 
key findings of our study is the sustained clinical long-
term benefit of CZP also in CD patients previously having 
received infliximab or adalimumab and even both agents.
 The clinical benefit regardless of disease duration ob-
served in our cohort appears to be in contrast to the pre-
vious literature with adalimumab  [29, 30] , certolizumab 
 [31], and infliximab in children  [32] , all of which suggest 
better response rates with shorter disease duration. In 
adults, however, response rates of infliximab did not ap-
pear to be associated with disease duration  [33–35] .
 Recently, retrospective long-term data on the efficacy 
of CZP were reported and identified early age of CD man-
ifestation, previous primary non-response to adalimum-
ab, and presence of perianal fistulizing disease as negative 
predictors of response  [36] . However, these patients rep-
resent a highly selected collective from a single large US 
tertiary referral center. In contrast to these single-center 
results, neither younger age nor prior treatment with 
adalimumab nor presence of fistulizing disease was asso-
ciated with a premature stop of CZP in our cohort (mean 
patient age 41.1 years, 50% B3 disease and 47.2% without 
prior adalimumab exposure in those patients still on CZP 
at last follow-up vs. 37.1 years, 44.1% B3 and 52.9% with-
out prior adalimumab in those patients where CZP was 
withdrawn).
 The availability of a selection different TNF-inhibiting 
agents represents an important clinical need due to sev-
eral reasons including primary non-response  [1, 2, 4, 6] 
LOR  [6] (where switching within class has revealed been 
to be a highly successful and safe option  [2, 6–8] ), and not 
terribly intriguing reported success rates of newly avail-
able or emerging treatment options. Moreover, the field 
of emerging treatment options in IBD currently appears 
to be evolving somewhat less impressively in CD as com-
pared to UC and those targets that are investigated in UC 
and CD, such as strategies addressing leucocyte migra-
tion or inhibition of JAK/STAT activation, seem to work 
better in the former.
 An important limitation of our study is the variable 
follow-up time per patient with only small patient num-
bers at the longest observational points. Moreover, endo-
scopic data or fecal calprotectin levels to undermine the 
clinically derived response were not available. Further-
more, predefined criteria for stopping the agent for uni-
form clinical practice were lacking. Strengths of our study 
include the long-term follow-up, the multicenter setting 
including gastroenterologists in private practice as well as 
academic centers, and the unselected study population 
with a high rate of previous anti-TNF exposure. Our 
study may thus represent a real-life scenario with diffi-
cult-to-treat CD patients.
 In summary, we identified CZP as an effective long-
term treatment option in CD patients regardless of the 
duration of their disease as well as prior exposure and 
clinical response to 1 or 2 anti-TNF agents in our long-
term observational study. Accordingly, and in view of the 
still limited alternative treatment options for CD patients 
with an insufficient response to infliximab and/or adali-
mumab, we conclude that there is definitely a place and 
also a need for a third TNF-inhibiting agent in the treat-
ment of CD.
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